US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

17.29

-0.4200-2.37%

Post-market: 17.290.00000.00%17:50 EDT

Volume:326.26K

Turnover:5.65M

Market Cap:1.04B

PE:-5.75

High:17.73

Open:17.27

Low:17.00

Close:17.71

Loading ...

Overview Company News Filings

Spyre Therapeutics Announces Inducement Stock Option Grants for New Employees Under 2018 Equity Plan

Spyre Therapeutics Inc. Convened Annual Stockholders Meeting

Spyre Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference

Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Spyre Therapeutics Inc: Expected Cash Runway Into Second Half of 2028

THOMSON REUTERS

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (Ddw) 2025 Including up to Eight Months of Follow-up From an Ongoing Phase 1 Trial of Spy001

THOMSON REUTERS

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Inc. Announces Inducement Awards Granting Stock Options to Non-Executive Employees Under 2018 Equity Plan

BUZZ-Leerink Partners begins coverage on Spyre Therapeutics with 'outperform'

Spyre Therapeutics Initiated at Outperform by Leerink Partners

Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target

MT Newswires Live

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target

MT Newswires Live

Spyre Therapeutics Announces Grants of Inducement Awards

JonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)

Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status

BRIEF-Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC Filing

Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":17.29,"timestamp":1749844800000,"preClose":17.71,"halted":0,"volume":326257,"hourTrading":{"tag":"盘后","latestPrice":17.29,"preClose":17.29,"latestTime":"17:50 EDT","volume":8651,"amount":149565.010854,"timestamp":1749851441764},"delay":0,"floatShares":46623089,"shares":60353561,"eps":-3.006383,"marketStatus":"Post-Mkt","change":-0.42,"latestTime":"06-13 19:48:57 EDT","open":17.27,"high":17.73,"low":16.995,"amount":5650089.689127,"amplitude":0.041502,"askPrice":20.16,"askSize":100,"bidPrice":15.48,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.006383,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749859200000},"marketStatusCode":4,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":17.71,"preHourTrading":{"tag":"盘前","latestPrice":17.64,"preClose":17.71,"latestTime":"09:28 EDT","volume":36,"amount":635.04,"timestamp":1749821280060},"postHourTrading":{"tag":"盘后","latestPrice":17.29,"preClose":17.29,"latestTime":"17:50 EDT","volume":8651,"amount":149565.010854,"timestamp":1749851441764},"volumeRatio":0.615567,"impliedVol":0.7322,"impliedVolPercentile":0.456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":46623089,"roa":"-25.34%","roe":"-65.82%","lyrEps":-3.180151,"volumeRatio":0.615567,"shares":60353561,"dividePrice":0,"high":17.73,"amplitude":0.041502,"preClose":17.71,"low":16.995,"week52Low":10.91,"pbRate":"3.19","week52High":40.26,"institutionHeld":0,"latestPrice":17.29,"eps":-3.006383,"divideRate":0,"volume":326257,"delay":0,"ttmEps":-3.006383,"open":17.27,"prevYearClose":23.28,"prevWeekClose":16.97,"prevMonthClose":15.28,"prevQuarterClose":16.135,"fiveDayClose":16.97,"twentyDayClose":14.54,"sixtyDayClose":18.4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541989088","title":"Spyre Therapeutics Announces Inducement Stock Option Grants for New Employees Under 2018 Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2541989088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541989088?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:05","pubTimestamp":1749240318,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc., a clinical-stage biotechnology company, announced on June 6, 2025, that its independent Compensation Committee has approved the grant of stock options to three non-executive employees. The inducement awards, granted under the company's 2018 Equity Inducement Plan, allow for the purchase of 50,200 shares of common stock at an exercise price of $15.40 per share, consistent with the closing price on June 2, 2025. These options come with a 10-year term and vest over a four-year period, beginning with one-fourth of the shares after the first year of employment, followed by monthly vesting of one-forty-eighth of the shares. These terms are contingent upon continuous service with Spyre.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL9M7CFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2540671803","title":"Spyre Therapeutics Inc. Convened Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540671803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540671803?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:02","pubTimestamp":1748894560,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. held its Annual Meeting of Stockholders on May 29, 2025. During the meeting, stockholders elected Peter Harwin, Michael Henderson, and Sandra Milligan as Class III directors. The stockholders also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL6FDdPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2538768664","title":"Spyre Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538768664","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538768664?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:30","pubTimestamp":1748435426,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. , a clinical-stage biotechnology company, is set to participate in the Jefferies Global Healthcare Conference on June 4, 2025. The company, known for its advancements in antibody engineering and therapeutic combinations for the treatment of Inflammatory Bowel Disease and other immune-mediated diseases, will have its management present at a fireside session scheduled for 8:10 am ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5Hfr2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2534913162","title":"Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534913162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534913162?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:55","pubTimestamp":1746737755,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummarySpyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 60 cents per share for the quarter ended Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG3HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2534648911","title":"Spyre Therapeutics Inc:  Expected Cash Runway Into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2534648911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534648911?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:33","pubTimestamp":1746736420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2533878586","title":"Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (Ddw) 2025 Including up to Eight Months of Follow-up From an Ongoing Phase 1 Trial of Spy001","url":"https://stock-news.laohu8.com/highlight/detail?id=2533878586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533878586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA51QP7W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2533586580","title":"Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586580","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586580?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease . SPY001 pharmacokinetic  data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab. SPY001 pharmacodynamic  data up to eight months showed that a single dose of SPY001 resulted in rapid and sustained saturation of α4β7 receptors at expected Phase 2 trough concentrations. Spyre presented results out to eight months of follow up from its SPY001 Phase 1 program.Updated results from our ongoing Phase 1 trial of SPY001, our novel half-life extended α4β7 antibody for the treatment of IBD, continues to show that SPY001 is well tolerated, has a half-life of more than three-fold compared to vedolizumab based on population PK modeling, and sustains target engagement at expected Phase 2 trough concentrations. This longer follow-up data strengthens the potential for SPY001 to demonstrate improved in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4218","BK4007","PD","BK4139","LU1169589451.USD","PK","LU1169590202.USD","SYRE","BK4181","BK4023","IBD"],"gpt_icon":0},{"id":"2532635871","title":"Spyre Therapeutics Inc. Announces Inducement Awards Granting Stock Options to Non-Executive Employees Under 2018 Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2532635871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532635871?lang=en_us&edition=fundamental","pubTime":"2025-05-03 04:05","pubTimestamp":1746216330,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 2, 2025 - Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced the approval of stock options as an equity inducement for seven non-executive employees. The company's independent Compensation Committee of the Board of Directors has granted options to purchase a total of 64,400 shares under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. Approved on May 1, 2025, the stock options have a 10-year term with an exercise price of $14.66, matching the closing price of Spyre's common stock on that date. The vesting schedule stipulates that one-fourth of the shares become exercisable on the first anniversary of the employee's start date, with the remainder vesting monthly over four years, contingent on continuous service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL10GsWv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2525489252","title":"BUZZ-Leerink Partners begins coverage on Spyre Therapeutics with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2525489252","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525489252?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:57","pubTimestamp":1744117076,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink Partners begins coverage on Spyre Therapeutics with 'outperform'** Biotech firm Spyre Therapeutics' SYRE.O shares rise 3% to $12.76 premarket** Brokerage Leerink Partners initiates coverage with \"outperform\" rating** Sets PT at $45, representing more than triple upside to the stock's last close     ** Leerink Partners view SYRE as one of \"the most compelling prospective entrants in inflammatory bowel disease\" ** SYRE said in January it will begin mid-stage study of monotherapies, SPY001 , followed by SPY002 , SPY003 , to treat ulcerative colitis in mid-2025 and expects results in 2026** Brokerage says \"SYRE is well-capitalized to execute on its near-term plans, and the cadence of data catalysts out of the platform trial will pick up dramatically in 2026-2027\"** Company has cash, cash equivalents, and marketable securities balance of over $600 million as of December 31, 2024** Ten of 11 brokerages rate the stock \"buy\" or higher, one \"hold\"; their median PT is $55.75, accord","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL3N3QM153:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2525889960","title":"Spyre Therapeutics Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2525889960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525889960?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:06","pubTimestamp":1744113960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SYRE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:06 ET (12:06 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2525985896","title":"Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2525985896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525985896?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:52","pubTimestamp":1744113178,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) has an average rating of Buy and mean price target of $54.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2525730381","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2525730381","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525730381?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:05","pubTimestamp":1743797100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 93,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on April 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500867.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SYRE","LENZ","IBD"],"gpt_icon":0},{"id":"2522319815","title":"Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003","url":"https://stock-news.laohu8.com/highlight/detail?id=2522319815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522319815?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106255,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life ex...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-says-first-patient-dosed-in-phase-1-trial-of-spy003?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-says-first-patient-dosed-in-phase-1-trial-of-spy003?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2522595385","title":"Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2522595385","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522595385?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies. Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025. SPY003 is an investigational, novel, extended half-life monoclonal antibody targeting IL-23, being developed for the potential treatment of IBD. IBD is a chronic condition characterized by inflammation in the gastrointestinal tract and encompasses two main disorders: ulcerative colitis and Crohn's disease. In the United States, it is estimated that approximately 2.4 million individuals currently have IBD. In head-to-head preclinical studies, SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly longer half-life in non-human primates with the potential to deliver dosing in h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PK","IBD","LENZ","BK4218","BK4181","SYRE"],"gpt_icon":0},{"id":"2520626310","title":"Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2520626310","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520626310?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:16","pubTimestamp":1742296588,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) has an average rating of buy and mean price target of $55.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2517466136","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2517466136","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517466136?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:40","pubTimestamp":1741383600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on March 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4139","SYRE","LENZ"],"gpt_icon":0},{"id":"2516800166","title":"JonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516800166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516800166?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:29","pubTimestamp":1741004970,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares close...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-hold-rating-for-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-hold-rating-for-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2516535729","title":"Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2516535729","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516535729?lang=en_us&edition=fundamental","pubTime":"2025-03-01 14:01","pubTimestamp":1740808897,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc (SYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Spyre Therapeutics, Inc. faces significa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-faces-compliance-hurdles-after-transition-from-smaller-reporting-company-status?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-faces-compliance-hurdles-after-transition-from-smaller-reporting-company-status?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0},{"id":"2514770356","title":"BRIEF-Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514770356","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514770356?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:23","pubTimestamp":1740695001,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC FilingFeb 27  - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS INC FILES FOR MIXED SHELF OFFERING OF UP TO $500 MILLION- SEC FILINGSource text: [ID:n0001628280-25-008686]Further company coverage: SYRE.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2514353725","title":"Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514353725?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:43","pubTimestamp":1740692590,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummarySpyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 81 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI38Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86},{"market":"US","date":"2024-05-09","symbol":"SYRE","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.25,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":12,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-06-12","current":-5.199556,"percent":0.410995,"low":-10.261647,"twenty":-7.178339,"median":-4.413064,"eighty":-3.545699,"high":-0.199399,"avg":-5.089431,"sd":1.951534,"marketCap":1086364098},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-12","current":-5.199556,"twenty":-7.178339,"median":-4.413064,"eighty":-3.545699,"marketCap":1086364098}],"updateTime":1749821066615}}}